The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...
A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...
Drugmaker Hikma’s generic version of Irish-American company Amarin Pharma’s cardiovascular medication Vascepa did not infringe Amarin’s patents, the US supreme court ruled on Thursday in a decision ...
Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its generic version of Amarin’s fish oil-derived cardiovascular drug Vascepa does not ...
WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...
US Supreme Court Backs Generic Drugmaker in 'Skinny Label' Patent Case By Blake Brittain WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's generic version of Amarin Pharma's cardiovascular medication ...
A practical guide to OpenCode — from your first prompt to custom agents, skills, plugins, and MCP integrations. Built around clear mental models and real examples, not marketing. Who this is for: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results